Gestational Weight Gain and Pregnancy Outcomes After GLP-1 Receptor Agonist Discontinuation
In a cohort composed primarily of women with obesity, GLP-1RA use with subsequent prepregnancy or early pregnancy discontinuation was associated with more gestational weight gain and a higher risk of preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy.
Authors
- Jacqueline Maya (ORCID: https://orcid.org/0000-0001-9836-3448)
- Tanayott Thaweethai (ORCID: https://orcid.org/0000-0003-0613-4176)
- Lydia L. Shook (ORCID: https://orcid.org/0000-0002-5859-8610)
- Kaitlyn E. James (ORCID: https://orcid.org/0000-0002-2267-372X)
- Sarah Hsu (ORCID: https://orcid.org/0000-0001-9823-9711)
- Marie‐France Hivert (ORCID: https://orcid.org/0000-0001-7752-2585)
- Diana C. Soria‐Contreras (ORCID: https://orcid.org/0000-0001-5783-5365)
- Christopher Mow (ORCID: https://orcid.org/0000-0003-4862-9230)
- Deepti Pant (ORCID: https://orcid.org/0000-0002-6890-081X)
- Camille Elise Powe (ORCID: https://orcid.org/0000-0002-7060-7778)
- Yiran Fu
- CAROLINA I. BATLLE
Institutions
- Broad Institute (US)
- Harvard University (US)
- University of Puerto Rico System (PR)
- Massachusetts General Hospital (US)
- Digital Science (United States) (US)
- Harvard Pilgrim Health Care (US)
Publication Details
- Journal
- JAMA
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1001/jama.2025.20951
- Citations
- 8
- Primary Topic
- Gestational Diabetes Research and Management
- Type
- article
- Field-Weighted Citation Impact
- 16.46